Publication: 4852

Publication: 4852

Health-related quality of life (HRQOL) in the phase III trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502, ATOMIC)

Google Scholar

Citation:

Meeting Instance:: ASCO 2026
Year:: 2026
Type:: Abstract
Sub type:
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:

Note:

Methodological:: No
Biospecimen:: No
SDC:: Yes

Parents:: None
Children:: None

Program:: CCP
Primary Committee:: Health Outcomes
Sec. Committees:: GI

Pharmas:: Genentech
Grants:: UG1CA189823, U10CA180821, U10CA180882

Corr. Author:
Authors:: Amylou C. Dueck Briant Fruth Dirk Arnold Walter Peters Robert J. Behrens Christopher Hanyoung Lieu Khalid Matin Deirdre J. Cohen Samara L. Potter Wendy L. Frankel Ardaman Shergill Dennis Hsu Anke C. Reinacher-Schick Tyler Zemla Clare A. Gatten Eileen M. O'Reilly Jeffrey A. Meyerhardt Fang-Shu Ou Frank A. Sinicrope

Networks:: IWORC, LAPS-CO070, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-NY016, LAPS-OH007, NY021, TX012, VCU

Study: Alliance-A021502
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords: